Kolmar BNH Co. Ltd (200130) - Total Liabilities
Based on the latest financial reports, Kolmar BNH Co. Ltd (200130) has total liabilities worth ₩294.21 Billion KRW (≈ $199.38 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 200130 cash flow conversion to assess how effectively this company generates cash.
Kolmar BNH Co. Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Kolmar BNH Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 200130 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Kolmar BNH Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Kolmar BNH Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sino AG
F:XTP
|
Germany | €2.06 Million |
|
AVY Precision Technology
TWO:5392
|
Taiwan | NT$6.90 Billion |
|
Audix Corp
TW:2459
|
Taiwan | NT$3.26 Billion |
|
Benz Mining Corp
F:1VU
|
Germany | €3.69 Million |
|
technotrans SE
F:TTR1
|
Germany | €68.21 Million |
|
Alx Oncology Holdings
NASDAQ:ALXO
|
USA | $37.92 Million |
|
Pact Group Holdings Ltd
AU:PGH
|
Australia | AU$1.55 Billion |
|
MFS Municipal Income Trust
NYSE:MFM
|
USA | $114.42 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Kolmar BNH Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 200130 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kolmar BNH Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kolmar BNH Co. Ltd (2014–2025)
The table below shows the annual total liabilities of Kolmar BNH Co. Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩294.21 Billion ≈ $199.38 Million |
+0.15% |
| 2024-12-31 | ₩293.77 Billion ≈ $199.09 Million |
-1.49% |
| 2023-12-31 | ₩298.21 Billion ≈ $202.09 Million |
+38.50% |
| 2022-12-31 | ₩215.31 Billion ≈ $145.92 Million |
+41.32% |
| 2021-12-31 | ₩152.36 Billion ≈ $103.25 Million |
-16.75% |
| 2020-12-31 | ₩183.01 Billion ≈ $124.02 Million |
+36.62% |
| 2019-12-31 | ₩133.95 Billion ≈ $90.78 Million |
+54.20% |
| 2018-12-31 | ₩86.87 Billion ≈ $58.87 Million |
-15.17% |
| 2017-12-31 | ₩102.40 Billion ≈ $69.40 Million |
+224.04% |
| 2016-12-31 | ₩31.60 Billion ≈ $21.42 Million |
+20.87% |
| 2015-12-31 | ₩26.14 Billion ≈ $17.72 Million |
+689.22% |
| 2014-12-31 | ₩3.31 Billion ≈ $2.24 Million |
-- |
About Kolmar BNH Co. Ltd
Kolmar BNH Co., Ltd. engages in the research and development of materials used in the functional health food and cosmetics market in South Korea and internationally. The company offers cosmetics; and provides total functional health food original development manufacturing services, such as manufacturing tablets, hard capsules, soft capsules, liquids, gels, powder dosage, and various new formulati… Read more